

**MATERIAL CHANGE REPORT
PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102
RESPECTING CONTINUOUS DISCLOSURE OBLIGATIONS**

ITEM 1: **Name and Address of Corporation**

Terranueva Corporation (“Terranueva” or the “Corporation”)
803, Boulevard de l’Ange Gardien
L’Assomption (Québec)
J5W 1T3

ITEM 2: **Date of Material Changes**

April 7, 2021.

ITEM 3: **News Release**

A press release was issued in English and French by Terranueva on April 7, 2021. Copies of each version are attached hereto.

ITEM 4: **Summary of Material Changes**

Terranueva, one of the 6 companies in Québec holding a licence from Health Canada to develop cannabis products for medical and recreational purposes, is pleased to announce that Canada Economic Development (“CED”) has granted the Corporation a \$500,000 loan to the business to support its day-to-day operations, bringing CED’s support to the Corporation to \$1 million to date.

ITEM 5: **Full Description of Material Changes**

Terranueva one of the 6 companies in Québec holding a licence from Health Canada to develop cannabis products for medical and recreational purposes, is pleased to announce that Canada Economic Development (“CED”) has granted the Corporation a \$500,000 loan to the business to support its day-to-day operations, bringing CED’s support to the Corporation to \$1 million to date.

This assistance from CED comes from the Regional Relief and Recovery Fund (“RRRF”), which is part of Canada’s COVID-19 Economic Response Plan.

“Following the conclusion of the recent private placement, by injecting another \$500,000 into our working capital, CED is allowing us to continue executing our strategic plan, particularly by supporting our research and development activities, by allowing us to continue producing our harvests in our MPU (modular production unit) and the development of innovative products,” underlines Peter Polatos, President and CEO of Terranueva.

ITEM 6: **Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

ITEM 7: **Omitted Information**

Not applicable.

ITEM 8 **Executive Officer**

For further information, please contact Mr. Peter Polatos, Director, President and Chief Executive Officer of the Corporation at (450) 591-1011.

ITEM 9: **Date of Report**

April 14, 2021.

TERRANUEVA CORPORATION



TERRANUEVA

PRESS RELEASE

FOR IMMEDIATE RELEASE

TICKER SYMBOL: TEQ

APRIL 7, 2021

TERRANUEVA GETS AN ADDITIONAL \$500,000 IN FINANCIAL SUPPORT FROM CANADA ECONOMIC DEVELOPMENT

L'ASSOMPTION, QUÉBEC – Terranueva Corporation (CSE : TEQ) (the “**Corporation**” or “**Terranueva**”), one of the 6 companies in Québec holding a licence from Health Canada to develop cannabis products for medical and recreational purposes, is pleased to announce that Canada Economic Development (“**CED**”) has granted the Corporation a \$500,000 loan to the business to support its day-to-day operations, bringing CED’s support to the Corporation to \$1 million to date.

This assistance from CED comes from the Regional Relief and Recovery Fund (“**RRRF**”), which is part of Canada’s COVID-19 Economic Response Plan.

“Following the conclusion of the recent private placement, by injecting another \$500,000 into our working capital, CED is allowing us to continue executing our strategic plan, particularly by supporting our research and development activities, by allowing us to continue producing our harvests in our MPU (modular production unit) and the development of innovative products,” underlines Peter Polatos, President and CEO of Terranueva.

ABOUT TERRANUEVA

Terranueva relies on research and development, innovation and operational efficiency to become a key player in the emerging cannabis industry. It aims to provide the Canadian and international markets with first-rate medicinal and recreational cannabis. To achieve its goal, Terranueva implements a modular production approach, integrating the latest advances and innovations in process automation. Terranueva Pharma Corporation, its wholly owned subsidiary, holds the necessary licences from Health Canada to accomplish its mission.

The Canadian Securities Exchange (CSE) has not in any way passed upon the merits of the anticipated operation and has neither approved nor disapproved the contents of this press release.

Neither the Canadian Securities Exchange (CSE) nor its Regulation Services Providers (as that term is defined in its policies) accept responsibility for the adequacy or accuracy of this press release.

For more information, please contact:

For Terranueva Corporation:

Dominique St-Louis
Chief Financial Officer
Telephone: 514.573.9066

CORPORATION TERRANUEVA



TERRANUEVA

COMMUNIQUÉ DE PRESSE

DIFFUSION IMMÉDIATE

SYMBOLE BOURSIER : TEQ

LE 7 AVRIL 2021

TERRANUEVA OBTIENT UNE AIDE FINANCIÈRE SUPPLÉMENTAIRE DE 500 000\$ DE DÉVELOPPEMENT ÉCONOMIQUE CANADA

L'ASSOMPTION, QUÉBEC – Corporation Terranueva (CSE : TEQ) (la « Société » ou « Terranueva »), une des 6 sociétés québécoises détentrices d'une licence de Santé Canada permettant de développer des produits médicaux et récréatifs à base de cannabis, est heureuse d'annoncer que Développement économique Canada (« DEC ») a accordé un prêt supplémentaire de 500 000 \$ à l'entreprise afin de soutenir ses opérations courantes, portant l'aide de DEC auprès de la Société à 1M\$ à ce jour.

Cette aide de DEC provient du Fonds d'aide et de relance régionale (« FARR »), lequel s'inscrit dans le Plan d'intervention économique du Canada pour répondre à la COVID-19.

« Suite à la conclusion du récent placement privé, en injectant de nouveau 500 000 \$ à notre fonds de roulement, DEC nous permet de poursuivre l'exécution de notre plan stratégique, notamment en soutenant nos activités de recherche et de développement, en nous permettant de poursuivre la production de nos récoltes dans notre UPM (unité de production modulaire) et le développement de produits novateurs », souligne Peter Polatos, président et chef de la direction de Terranueva.

À PROPOS DE TERRANUEVA

Terranueva s'appuie sur la recherche et développement, l'innovation et l'efficacité opérationnelle pour devenir un acteur incontournable dans l'industrie émergente du cannabis. Son objectif est de fournir sur le marché canadien comme à l'international, du cannabis médical et récréatif de première qualité. Pour atteindre son objectif, Terranueva met en œuvre une approche de production modulaire intégrant les dernières avancées et innovations dans l'automatisation de ces processus. Corporation Terranueva Pharma,

sa filiale détenue en propriété exclusive, détient les licences nécessaires de Santé Canada pour exécuter sa mission.

La Bourse de valeurs canadiennes (CSE) ne s'est nullement prononcée sur le bien-fondé de l'opération projetée, et n'a ni approuvé ou ni désapprouvé le contenu du présent communiqué.

La Bourse de valeurs canadiennes (CSE) et ses fournisseurs de services de réglementation (au sens attribué à ce terme dans ses politiques) n'assument aucune responsabilité quant à la pertinence ou à l'exactitude du présent communiqué.

Pour plus d'information, veuillez contacter :

Pour Corporation Terranueva :

Dominique St-Louis
Chef de la direction financière
Téléphone : 514.573.9066